PARP inhibitors target ATM+p53-defective gastric cancer

Curtin, Nicola J.

doi:10.4161/15384101.2014.948787

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experimental evidence suggests that ATM holds promise as a predictive biomarker for the efficacy of PARPi in GC, especially in the context of ATM mutations. The use of PARPi can selectively target P53-deficient GC cells that exhibit sensitivity [99,100]. BRCA, as the pioneering "synthetic lethal" gene targeted by PARPi, exhibits significant differences in risk score, NtAI score, HRD-LOH score, LST score, and HRD score between wild-type and mutant cases of BRCA2 in GC patients, making it a predictive biomarker for the response to DNA-damaging agents in these patients [101,102].…”

Section: Homologous Recombination Deficiency In Gcmentioning

confidence: 99%

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer

Chen,

Hu,

Zhuang

et al. 2023

Cancers

View full text Add to dashboard Cite

Gastric cancer (GC) is a common and aggressive cancer of the digestive system, exhibiting high aggressiveness and significant heterogeneity. Despite advancements in improving survival rates over the past few decades, GC continues to carry a worrisome prognosis and notable mortality. As a result, there is an urgent need for novel therapeutic approaches to address GC. Recent targeted sequencing studies have revealed frequent mutations in DNA damage repair (DDR) pathway genes in many GC patients. These mutations lead to an increased reliance on poly (adenosine diphosphate-ribose) polymerase (PARP) for DNA repair, making PARP inhibitors (PARPi) a promising treatment option for GC. This article presents a comprehensive overview of the rationale and development of PARPi, highlighting its progress and challenges in both preclinical and clinical research for treating GC.

show abstract